CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exo Therapeutics, Inc., a pre-clinical company developing a pipeline of drug candidates that target exosites, unique small-molecule binding pockets that are distal to traditional active and allosteric sites, thereby reprogramming enzyme activity for precise and robust therapeutic effect, announced a late breaking poster presentation at American College of Rheumatology’s Convergence (ACR) taking place November 14-19, 2024 in Washington, D.C.
Details of the poster presentations are as follows:
Abstract Title: Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Presenting Author: Bhavatarini Vangamudi, Ph.D.
Presentation Type: Poster
Session: Late-Breaking Posters (L01 - L14)
Date: Monday, November 18
Presentation Time: 10:30 AM - 12:30 PM
Abstract ID: 1943848
Final Number: L01
About Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company co-founded by Professors David R. Liu, Alan Saghatelian, and Juan Pablo Maianti with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in inflammation, oncology and a broad range of other diseases. For more information, visit www.exo-therapeutics.com.
